XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Inventory, Net
 3 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
Inventory, Net Inventory, Net
All of the Company's inventory relates to the manufacturing of MARGENZA. The following table sets forth the Company's net inventory (in thousands):
March 31, 2023December 31, 2022
Work in process$206 $409 
Finished goods1,203 1,042 
Total inventory, net$1,409 $1,451 
Prior to U.S. Food and Drug Administration (FDA) approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of March 31, 2023 and December 31, 2022 is net of a reserve of $4.9 million for unsaleable inventory. These reserves are reflected in cost of product sales during the period they are recorded.